Markets:

Overview

News

Currencies

International

Treasuries

ADC Therapeutics SA Common Shares (NY:ADCT)

3.710 -0.190 (-4.87%)

Streaming Delayed Price Updated: 10:14 AM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >

Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial

July 11, 2022

From ADC Therapeutics SA

Via Business Wire

Why ADC Therapeutics Shares Are Rising Today ↗

July 08, 2022

ADC Therapeutics SA (NYSE: ADCT) shares are trading higher by 11.56% to $10.23 Friday afternoon after the company entered into an exclusive license agreement with Swedish Orphan Biovitrum for the...

Via Benzinga

The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug ↗

July 08, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

ADC Therapeutics, Sobi Ink European Licensing Pact For Lymphoma Drug ↗

July 08, 2022

Via Benzinga

Analyst Ratings for ADC Therapeutics ↗

May 10, 2022

Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter:

Via Benzinga

ADC Therapeutics: Q1 Earnings Insights ↗

May 09, 2022

ADC Therapeutics (NYSE:ADCT) reported its Q1 earnings results on Monday, May 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Recap: ADC Therapeutics Q4 Earnings ↗

March 03, 2022

ADC Therapeutics (NYSE:ADCT) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement....

Via Benzinga

ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International Territories

July 08, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors

July 01, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents

June 29, 2022

From ADC Therapeutics SA

Via Business Wire

HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications ↗

June 13, 2022

Via Benzinga

ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer

June 13, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma

June 10, 2022

From ADC Therapeutics

Via Business Wire

ADC Therapeutics to Present at the Jefferies Healthcare Conference

June 01, 2022

From ADC Therapeutics SA

Via Business Wire

Stocks That Hit 52-Week Lows On Tuesday ↗

May 17, 2022

On Tuesday, 123 stocks made new 52-week lows.

Via Benzinga

ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress

May 12, 2022

From ADC Therapeutics SA

Via Business Wire

RBC Capital Maintains Outperform Rating for ADC Therapeutics: Here's What You Need To Know ↗

May 10, 2022

RBC Capital has decided to maintain its Outperform rating of ADC Therapeutics (NYSE:ADCT) and lower its price target from $34.00 to $30.00. Shares of ADC Therapeutics are trading down 1.34% over the...

Via Benzinga

Mid-Afternoon Market Update: Crude Oil Down 6%; Palantir Technologies Shares Slide ↗

May 09, 2022

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 400 points on Monday.

Via Benzinga

Mid-Day Market Update: Nasdaq Dips 450 Points; Hemisphere Media Group Shares Surge ↗

May 09, 2022

U.S. stocks extended losses midway through trading, with the Nasdaq Composite dropping around 450 points on Monday.

Via Benzinga

90 Biggest Movers From Yesterday ↗

May 10, 2022

Gainers

Via Benzinga

40 Stocks Moving In Monday's Mid-Day Session ↗

May 09, 2022

Gainers

Via Benzinga

ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

May 09, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Announces CEO Transition

May 09, 2022

From ADC Therapeutics SA

Via Business Wire

Earnings Outlook For ADC Therapeutics ↗

May 06, 2022

ADC Therapeutics (NYSE:ADCT) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that ADC...

Via Benzinga

ADC Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

May 04, 2022

From ADC Therapeutics SA

Via Business Wire

How To Attend ADC Therapeutics Q1 2022 Earnings Conference Call ↗

May 04, 2022

ADC Therapeutics (NYSE:ADCT) will host a conference call at 08:30 AM ET on May 9, 2022, to discuss Q1 2022 earnings results. How to Attend ADC Therapeutics (ADCT) Conference Call Follow this link to...

Via Benzinga

ADC Therapeutics to Host First Quarter 2022 Financial Results Conference Call on May 9, 2022

May 03, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Receives Permanent J-Code for ZYNLONTA® (J9359) from U.S. Centers for Medicare & Medicaid Services

April 04, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2021

March 17, 2022

From ADC Therapeutics SA

Via Business Wire

Cantor Fitzgerald Cuts ADC Therapeutics Price Target On 'Repositioned Zynlonta Pipeline Strategy' ↗

March 04, 2022

Following Q4 FY21 results, Cantor Fitzgerald has lowered the price target on ADC Therapeutics SA (NASDAQ: ADCT) to $26 from $45 and keeps an Overweight rating...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

ADC Therapeutics SA Common Shares (NY:ADCT)

All News about ADC Therapeutics SA Common Shares

Starting at $3.75/week.

Subscribe Today